CTIS2022-500905-42-00招募中1 期
38RC22.0211 LAP NET1
niversity Hospital Grenoble0 个研究点目标入组 52 人开始时间: 2022年8月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular carcinomaunresectable hepatocellular carcinomaCTIS2022-500903-38-00niversity Hospital Grenoble52
进行中（未招募）
1 期
A Study of ASP2138 in Adults With Stomach Cancer or Pancreatic Cancer.CTIS2023-504514-29-00Astellas Pharma Global Development Inc.240
进行中（未招募）
1 期
Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 in Patients of 60 years old or more With adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)Adult patients with adverse Risk Acute Myeloblastic LeukemiaCTIS2022-502585-25-00Centre Hospitalier Universitaire De Nantes12
进行中（未招募）
1 期
First administration in healthy volunteers of a single and increasing dose of a new molecule for the treatment of brain diseasesPost-Traumatic Stress Disorder (PTSD)MedDRA version: 21.1Level: PTClassification code: 10036316Term: Post-traumatic stress disorder Class: 100000004873CTIS2023-505030-99-00Rest Therapeutics36
招募中
1 期
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2DCTIS2023-508054-25-01anexa AB9